Display options
Cite
Boyce RD, Horn JR, Hassanzadeh O, et al. Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. J Biomed Semantics. 2013;4(1):5doi: 10.1186/2041-1480-4-5.
Boyce, R. D., Horn, J. R., Hassanzadeh, O., Waard, A. d., Schneider, J., Luciano, J. S., Rastegar-Mojarad, M., & Liakata, M. (2013). Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. Journal of biomedical semantics, 4(1), 5. https://doi.org/10.1186/2041-1480-4-5
Boyce, Richard D, et al. "Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness." Journal of biomedical semantics vol. 4,1 (2013): 5. doi: https://doi.org/10.1186/2041-1480-4-5
Boyce RD, Horn JR, Hassanzadeh O, Waard Ad, Schneider J, Luciano JS, Rastegar-Mojarad M, Liakata M. Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. J Biomed Semantics. 2013 Jan 26;4(1):5. doi: 10.1186/2041-1480-4-5. PMID: 23351881; PMCID: PMC3698101.
Copy Download .nbib Format: NLM
Share it on

J Biomed Semantics. 2013 Jan 26;4(1):5. doi: 10.1186/2041-1480-4-5.

Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness.

Journal of biomedical semantics

Richard D Boyce, John R Horn, Oktie Hassanzadeh, Anita de Waard, Jodi Schneider, Joanne S Luciano, Majid Rastegar-Mojarad, Maria Liakata

Affiliations

  1. Department of Biomedical Informatics, University of Pittsburgh, Offices at Baum, 5607 Baum Blvd, Pittsburgh, PA, USA. [email protected].

PMID: 23351881 PMCID: PMC3698101 DOI: 10.1186/2041-1480-4-5

Abstract

Out-of-date or incomplete drug product labeling information may increase the risk of otherwise preventable adverse drug events. In recognition of these concerns, the United States Federal Drug Administration (FDA) requires drug product labels to include specific information. Unfortunately, several studies have found that drug product labeling fails to keep current with the scientific literature. We present a novel approach to addressing this issue. The primary goal of this novel approach is to better meet the information needs of persons who consult the drug product label for information on a drug's efficacy, effectiveness, and safety. Using FDA product label regulations as a guide, the approach links drug claims present in drug information sources available on the Semantic Web with specific product label sections. Here we report on pilot work that establishes the baseline performance characteristics of a proof-of-concept system implementing the novel approach. Claims from three drug information sources were linked to the Clinical Studies, Drug Interactions, and Clinical Pharmacology sections of the labels for drug products that contain one of 29 psychotropic drugs. The resulting Linked Data set maps 409 efficacy/effectiveness study results, 784 drug-drug interactions, and 112 metabolic pathway assertions derived from three clinically-oriented drug information sources (ClinicalTrials.gov, the National Drug File - Reference Terminology, and the Drug Interaction Knowledge Base) to the sections of 1,102 product labels. Proof-of-concept web pages were created for all 1,102 drug product labels that demonstrate one possible approach to presenting information that dynamically enhances drug product labeling. We found that approximately one in five efficacy/effectiveness claims were relevant to the Clinical Studies section of a psychotropic drug product, with most relevant claims providing new information. We also identified several cases where all of the drug-drug interaction claims linked to the Drug Interactions section for a drug were potentially novel. The baseline performance characteristics of the proof-of-concept will enable further technical and user-centered research on robust methods for scaling the approach to the many thousands of product labels currently on the market.

References

  1. J Biomed Inform. 2010 Apr;43(2):173-89 - PubMed
  2. Ann Pharmacother. 2012 Oct;46(10):1287-98 - PubMed
  3. Bioinformatics. 2012 Apr 1;28(7):991-1000 - PubMed
  4. Drug Saf. 2008;31(6):525-36 - PubMed
  5. Arch Intern Med. 2011 May 23;171(10):944-6 - PubMed
  6. Clin Ther. 2011 Jan;33(1):36-45 - PubMed
  7. J Biomed Inform. 2012 Apr;45(2):231-9 - PubMed
  8. J Chem Inf Model. 2011 Nov 28;51(11):2977-85 - PubMed
  9. Trends Biotechnol. 2010 Jul;28(7):381-90 - PubMed
  10. J Biomed Inform. 2009 Dec;42(6):990-1003 - PubMed
  11. Clin Pharmacokinet. 2002;41(3):161-9 - PubMed
  12. Brief Bioinform. 2005 Mar;6(1):57-71 - PubMed
  13. J Cheminform. 2011 May 16;3(1):19 - PubMed
  14. Clin Pharmacol Ther. 2010 Jan;87(1):48-51 - PubMed
  15. J Biomed Inform. 2010 Dec;43(6):1009-19 - PubMed
  16. PLoS Comput Biol. 2012;8(8):e1002614 - PubMed
  17. Stud Health Technol Inform. 2004;107(Pt 1):477-81 - PubMed
  18. J Am Geriatr Soc. 2005 May;53(5):891-4 - PubMed
  19. Pac Symp Biocomput. 2012;:410-21 - PubMed
  20. Drug Metab Dispos. 2001 Aug;29(8):1102-9 - PubMed
  21. Mol Syst Biol. 2010;6:343 - PubMed
  22. Am J Health Syst Pharm. 2011 May 15;68(10):941-6 - PubMed
  23. Bioinformatics. 2010 Sep 15;26(18):i547-53 - PubMed
  24. J Biomed Inform. 2009 Dec;42(6):979-89 - PubMed
  25. Am J Geriatr Pharmacother. 2012 Apr;10(2):139-50 - PubMed
  26. J Biomed Inform. 2008 Oct;41(5):739-51 - PubMed
  27. Biometrics. 1977 Mar;33(1):159-74 - PubMed

Publication Types